Fanconi Anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments

Cancer Letters

Volumn 292, Issue 1, 2010, Pages 73-79

  Kachnic, Lisa A ^a,b   Li, Li ^a   Fournier, Loreen ^a   Willers, Henning ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

FANCA; FANCD2; Fanconi Anemia; Platinum drugs

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CISPLATIN; FANCONI ANEMIA GROUP A PROTEIN; FANCONI ANEMIA GROUP C PROTEIN; FANCONI ANEMIA GROUP D2 PROTEIN; MITOMYCIN C; OXALIPLATIN; RAD51 PROTEIN; ANTINEOPLASTIC AGENT; FANCONI ANEMIA PROTEIN; PLATINUM COMPLEX;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; EMBRYO; EPIGENETICS; FIBROBLAST CULTURE; GENE INACTIVATION; GENE MUTATION; GENETIC HETEROGENEITY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; SQUAMOUS CELL CARCINOMA; CELL LINE; DRUG EFFECT; DRUG RESISTANCE; FIBROBLAST; GENETICS; HEAD AND NECK TUMOR; METABOLISM; MUTATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE; FANCONI ANEMIA COMPLEMENTATION GROUP A PROTEIN; FANCONI ANEMIA COMPLEMENTATION GROUP C PROTEIN; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; FANCONI ANEMIA COMPLEMENTATION GROUP PROTEINS; FIBROBLASTS; HEAD AND NECK NEOPLASMS; HUMANS; MUTATION; ORGANOPLATINUM COMPOUNDS;

EID: 77951239896     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.11.009     Document Type: Article

References (34)

1. Bagby G.C., Alter B.P. Fanconi anemia. Semin. Hematol. 2006, 43:147-156.
2. Kennedy R.D., D'Andrea A.D. The Fanconi anemia/BRCA pathway: new faces in the crowd. Genes Dev. 2005, 19:2925-2940.
3. Niedernhofer L.J., Lalai A.S., Hoeijmakers J.H. Fanconi anemia (cross)linked to DNA repair. Cell 2005, 123:1191-1198.
4. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat. Rev. Genet. 2007, 8:735-748.
5. Smogorzewska A., Matsuoka S., Vinciguerra P., McDonald E.R., Hurov K.E., Luo J., Ballif B.A., Gygi S.P., Hofmann K., D'Andrea A.D., Elledge S.J. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell 2007, 129:289-301.
6. Digweed M., Rothe S., Demuth I., Scholz R., Schindler D., Stumm M., Grompe M., Jordan A., Sperling K. Attenuation of the formation of DNA-repair foci containing RAD51 in Fanconi anaemia. Carcinogenesis 2002, 23:1121-1126.
7. Garcia-Higuera I., Taniguchi T., Ganesan S., Meyn M.S., Timmers C., Hejna J., Grompe M., D'Andrea A.D. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell 2001, 7:249-262.
8. Wang X., Andreassen P.R., D'Andrea A.D. Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Mol. Cell Biol. 2004, 24:5850-5862.
9. Matsushita N., Kitao H., Ishiai M., Nagashima N., Hirano S., Okawa K., Ohta T., Yu D.S., McHugh P.J., Hickson I.D., Venkitaraman A.R., Kurumizaka H., Takata M. A FancD2-monoubiquitin fusion reveals hidden functions of Fanconi anemia core complex in DNA repair. Mol. Cell 2005, 19:841-847.
10. Medhurst A.L., Laghmani el H., Steltenpool J., Ferrer M., Fontaine C., de Groot J., Rooimans M.A., Scheper R.J., Meetei A.R., Wang W., Joenje H., de Winter J.P. Evidence for subcomplexes in the Fanconi anemia pathway. Blood 2006, 108:2072-2080.
11. Wilson J.B., Yamamoto K., Marriott A.S., Hussain S., Sung P., Hoatlin M.E., Mathew C.G., Takata M., Thompson L.H., Kupfer G.M., Jones N.J. FANCG promotes formation of a newly identified protein complex containing, BRCA2, FANCD2 and XRCC3. Oncogene 2008, 27:3641-3652.
12. Willers H., Kachnic L.A., Luo C.M., Li L., Purschke M., Borgmann K., Held K.D., Powell S.N. Biomarkers and mechanisms of FANCD2 function. J. Biomed. Biotechnol. 2008, 2008:821529.
13. Gordon S.M., Alon N., Buchwald M. FANCC, FANCE, and FANCD2 form a ternary complex essential to the integrity of the Fanconi anemia DNA damage response pathway. J. Biol. Chem. 2005, 280:36118-36125.
14. Howlett N.G., Harney J.A., Rego M.A., Kolling F.W.t., Glover T.W. Functional interaction between the Fanconi anemia D2 protein and proliferating cell nuclear antigen (PCNA) via a conserved putative PCNA interaction motif. J. Biol. Chem. 2009, 284:28935-28942.
15. Lyakhovich A., Surralles J. Disruption of the Fanconi anemia/BRCA pathway in sporadic cancer. Cancer Lett. 2006, 232:99-106.
16. Marsit C.J., Liu M., Nelson H.H., Posner M., Suzuki M., Kelsey K.T. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 2004, 23:1000-1004.
17. Wreesmann V.B., Estilo C., Eisele D.W., Singh B., Wang S.J. Downregulation of Fanconi anemia genes in sporadic head and neck squamous cell carcinoma. ORL J. Otorhinolaryngol. Relat. Spec. 2007, 69:218-225.
18. van Zeeburg H.J., Snijders P.J., Pals G., Hermsen M.A., Rooimans M.A., Bagby G., Soulier J., Gluckman E., Wennerberg J., Leemans C.R., Joenje H., Brakenhoff R.H. Generation and molecular characterization of head and neck squamous cell lines of Fanconi anemia patients. Cancer Res. 2005, 65:1271-1276.
19. Kennedy R.D., D'Andrea A.D. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J. Clin. Oncol. 2006, 24:3799-3808.
20. Burkitt K., Ljungman M. Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines. Cancer Lett. 2007, 253:131-137.
21. Van Der Heijden M.S., Brody J.R., Kern S.E. Functional screen of the Fanconi anemia pathway in cancer cells by Fancd2 immunoblot. Cancer Biol. Ther. 2004, 3:534-537.
22. Jakobs P.M., Sahaayaruban P., Saito H., Reifsteck C., Olson S., Joenje H., Moses R.E., Grompe M. Immortalization of four new Fanconi anemia fibroblast cell lines by an improved procedure. Somat. Cell. Mol. Genet. 1996, 22:151-157.
23. Silva O.E., Tolba K., Farfan N., Karr M., Calfa C., Raez L.E. Oxaliplatin and capecitabine (XELOX) as first-line therapy for metastatic or relapsed squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2007, 25:16524.
24. Cohen E.E., Rosine D., Haraf D.J., Loh E., Shen L., Lusinchi A., Vokes E.E., Bourhis J. Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2007, 67:678-684.
25. Thompson L.H., Hinz J.M. Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights. Mutat. Res. 2009, 668:54-72.
26. Ferrer M., Rodriguez J.A., Spierings E.A., de Winter J.P., Giaccone G., Kruyt F.A. Identification of multiple nuclear export sequences in Fanconi anemia group A protein that contribute to CRM1-dependent nuclear export. Hum. Mol. Genet. 2005, 14:1271-1281.
27. Ferrer M., de Winter J.P., Mastenbroek D.C., Curiel D.T., Gerritsen W.R., Giaccone G., Kruyt F.A. Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA. Cancer Gene Ther. 2004, 11:539-546.
28. Ishida R., Buchwald M. Susceptibility of Fanconi's anemia lymphoblasts to DNA-cross-linking and alkylating agents. Cancer Res. 1982, 42:4000-4006.
29. Brown J.M., Wouters B.G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 1999, 59:1391-1399.
30. Hanada K., Budzowska M., Modesti M., Maas A., Wyman C., Essers J., Kanaar R. The structure-specific endonuclease Mus81-Eme1 promotes conversion of interstrand DNA crosslinks into double-strands breaks. Embo. J. 2006, 25:4921-4932.
31. Dendouga N., Gao H., Moechars D., Janicot M., Vialard J., McGowan C.H. Disruption of murine Mus81 increases genomic instability and DNA damage sensitivity but does not promote tumorigenesis. Mol. Cell Biol. 2005, 25:7569-7579.
32. Kim J.M., Parmar K., Huang M., Weinstock D.M., Ruit C.A., Kutok J.L., D'Andrea A.D. Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. Dev. Cell. 2009, 16:314-320.
33. Pagano G., Degan P., d'Ischia M., Kelly F.J., Nobili B., Pallardo F.V., Youssoufian H., Zatterale A. Oxidative stress as a multiple effector in Fanconi anaemia clinical phenotype. Eur. J. Haematol. 2005, 75:93-100.
34. Pagano G., Youssoufian H. Fanconi anaemia proteins: major roles in cell protection against oxidative damage. Bioessays 2003, 25:589-595.